Skip to main content

09-27-2017 | Dyslipidemia | Review | Article

Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions

Current Diabetes Reports

Authors: Alan Chait, Ira Goldberg

Publisher: Springer US


Purpose of Review

This article reviews current knowledge concerning diabetic dyslipidemia and cardiovascular disease (CVD). It reviews strategies to reduce diabetes-associated CVD, including reducing low-density lipoprotein levels, lowering triglycerides, and increasing high-density lipoproteins (HDL). Special considerations, such as the multifactorial chylomicronemia syndrome and partial lipodystrophy, and the role of glucose-lowering strategies in the management of diabetic dyslipidemia are discussed.

Recent Findings

The strongest evidence to date for reducing CVD in diabetes comes from the use of statins. While triglyceride lowering remains inconclusive, an ongoing trial might provide some finality to this question. The role of increasing HDL remains elusive, and HDL cholesterol appears to be an unsatisfactory metric for monitoring therapy.


The use of statins offers the best current way to reduce diabetes-associated CVD. However, several novel and promising approaches for the management of diabetic dyslipidemia aimed at reducing CVD are in the pipeline.

Please log in to get access to this content

Related topics

Flash glucose monitoring technology

Browse new slide sets summarizing the latest results from real-world studies.

Image Credits